PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31850230-3 2019 A targeted macrocyclic gadolinium-based contrast agent (GBCA) ZD2-N3-Gd(HP-DO3A) (MT218), specific to EDB-FN, was developed for MRMI of aggressive breast cancer. Gadolinium 23-33 fibronectin 1 Homo sapiens 102-105 31850230-5 2019 At clinical dose of 0.1 and subclinical dose of 0.04 mmol Gd/kg, MT218 rapidly bound to the extracellular matrix EDB-FN and produced robust tumor contrast enhancement in both the tumor models, as early as 1-30 min post-injection. Gadolinium 58-60 fibronectin 1 Homo sapiens 113-116